No significant difference between LAMAs and LABAs in treating persistent asthma, research finds
Data from 15 randomised trials show that while long-acting muscarinic antagonists reduced exacerbation risk by a third, there was no significant improvement compared with long-acting beta-agonists.
Source: Science Photo Library
Long-acting beta-agonists (LABAs), such as salmeterol, are currently the primary add-on therapy for patients with persistent asthma. However, the comparative efficacy of long-acting muscarinic antagonists (LAMAs), such as tiotropium bromide, is less clear.
To explore, researchers carried out a systematic review and meta-analysis of 15 randomised trials comparing a LAMA with placebo or a LABA, as add-on therapy to inhaled corticosteroids (ICS) in 7,122 patients with persistent asthma.
The data show that LAMAs reduced the risk of exacerbations requiring systemic corticosteroids by 33% and asthma worsening by 19%, compared with placebo, but there was no significant improvement compared with LABA therapy. The researchers also discovered that triple therapy (ICS+LABA+LAMA) provided no additional benefit over ICS+LABA with regards to exacerbation risk.
Reporting in JAMA (online, 19 March 2018), the researchers said the current evidence does not suggest a significant difference between LABAs and LAMAs in preventing exacerbations but further studies are needed to determine if either is superior.
Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20204704
Recommended from Pharmaceutical Press
All you need to know about prescribing or administering drugs via enteral feeding tubes. Over 400 drug monographs as well as facts to inform clinical decision making.